Kiniksa Pharmaceuticals (KNSA) Stock Statistics & Valuation Metrics

Kiniksa Pharmaceuticals has a market cap or net worth of $1.93B. The enterprise value is ―.

Kiniksa Pharmaceuticals has 42,336,227 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kiniksa Pharmaceuticals’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -11.31%.

The current PE Ratio of Kiniksa Pharmaceuticals is -32.71. Kiniksa Pharmaceuticals’s PEG ratio is -1.92.

In the last 12 months, Kiniksa Pharmaceuticals had revenue of 423.24M and earned -43.19M in profits. Earnings per share was -0.60.

In the last 12 months, operating cash flow was 44.03M and capital expenditures -292.00K, giving a free cash flow of 43.73M billion.

Kiniksa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Kiniksa Pharmaceuticals upcoming earnings date is Jul 29, 2025, TBA Not Confirmed.

Kiniksa Pharmaceuticals as a current ratio of 3.30, with Debt / Equity ratio of 2.17%

In the past 12 months, Kiniksa Pharmaceuticals has paid 7.04M in taxes.

Kiniksa Pharmaceuticals EV to EBITDA ratio is -27.16, with an EV/FCF ratio of 48.76.

Kiniksa Pharmaceuticals has $268.34M in cash and marketable securities with $9.91M in debt, giving a net cash position of -$258.43M billion.

Gross margin is 81.02%, with operating margin of -10.78%, and net profit margin of -10.21%.

The average price target for Kiniksa Pharmaceuticals is $38.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy